Replies to post #772496 on NorthWest Biotherapeutics Inc (NWBO)

[Zadie420]

Thanks for brining it up. I was wonder about that too.
It is time NWBO performs these trials instead relying on third party involvement. Even taken at small sample like N<40 to show DCVAx L/D or combo with Poly-ICLC great performance. It has taken so long and many patients have died because of Greed on BP parts as well HFs.

[Galzus Research]

This man is ridiculous.

Likely reasons include:

– Data locked under NDA

– Publication rights negotiated away

– Results too sensitive to disclose
– Or NWBO delaying leverage disclosure

Sure, sure. NDA locking, ok.

Caravello isn't aware of other reasons that clinical trials get quitly shut down ALL THE TIME. Failure to find enough patients to enroll...shift in priorities of one or both parties...timelines not being met...principal partner (NWBO) not meeting its obligations. Who knows?

The most logical explanation is not that Merck is targeting poor little diamond in the rough NWBO.

Was poly-ICLC (Hiltonol) also part of the stack?

If it was never in the trial protocol, then no. It was never part of "the stack." That we need to use workout/lifestyle slang to convey this messaging in the first place is an indictment of the rigor with which this article was built, by the way.



So the conclusion here, unstated, goes:

1) Merck started up a collaboration with NWBO
2) A trial in MSS-CRC begins. Merck secretly includes Hiltonol in the soup recipe (makes as much sense as saying "stack) because reasons. None of this was disclosed in the trial protocol, therefore not to the doctors actually enrolling in the trial.
3) No one at any level is bothered at all by any of this secrecy
4) Merck (maybe...probably, wink wink) found some kind of efficacy in MSS-CRC, which would be one of the holy grails in oncology, and decided to erase the trial from existence. None of the trial investigators ever mentioned it again, and the data are coming....or maybe not.

Or maybe Merck is crushing little-old-NWBO's throat. Did you see that they had a partnership with SGEN a while ago?

Or actually no Merck is going to buy NWBO for $450 billion.

Or actually no NWBO is going to buy Merck. Probably.

[2B_unknown]

maverick_1,

Thank you and dstock for bringing this to our attention...again.

If all true, I wonder, why would NWBO ever have anything to do with Merck again?
I don't see that we need Merck for anything!

Turnabout is fair play against suppressors.

tbu

[USAFpatriot]

Could this be categorized as a criminal coverup?

[exwannabe]

Man, I should have read that closer. I missed this:

Ongoing lung, ovarian, and prostate trials

You are talking about trials announced literally 24 years ago. 2 of which never ran. Prostate was officially withdrawn on clinicaltrials.gov. Lung never registered.
There was an ovarian P1 ran by U Pen, but the P2 was withdrawn in favor of alternate DC tech.

And you assert they are ongoing? Not even Dr Strange could track down your reality.

From 2001 SEC

DCVax. DCVax is a dendritic cell-based cancer immunotherapy platform. Our DCVax therapies are designed to safely elicit potent immune responses that eliminate cancer cells. We are currently developing four DCVax product candidates. Our lead DCVax product candidate, DCVax-Prostate, is a prostate
cancer treatment for which we are planning a Phase III clinical trial. We have observed stabilization of disease in 54% of the patients in our Phase I/II
clinical trial, and a PSMA-specific immune response to DCVax-Prostate in 75% of patients. To date, we have observed no significant adverse side effects from
DCVax-Prostate. Our second DCVax product candidate, DCVax-Brain, is moving towards a Phase II clinical trial for glioblastoma, a lethal form of brain
cancer. Our third DCVax product candidate, DCVax-Lung, is moving towards a Phase I clinical trial for non-small cell carcinoma, the most prevalent form of lung
cancer. Our fourth DCVax product candidate is designed to treat renal cancer and is in pre-clinical development.